Agios Pharmaceuticals DEF 14A Filing Details Executive Compensation
Ticker: AGIO · Form: DEF 14A · Filed: Apr 25, 2025 · CIK: 1439222
| Field | Detail |
|---|---|
| Company | Agios Pharmaceuticals, Inc. (AGIO) |
| Form Type | DEF 14A |
| Filed Date | Apr 25, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: proxy-statement, executive-compensation, corporate-governance
TL;DR
Agios Pharma's 2025 DEF 14A is out, detailing exec pay and board matters for FY24. Goff & Fouse are key figures.
AI Summary
Agios Pharmaceuticals, Inc. filed its DEF 14A on April 25, 2025, for the fiscal year ending December 31, 2024. The filing details executive compensation and other corporate governance matters. Key individuals mentioned include Brian Goff and Jacqualyn A. Fouse, both members involved in compensation discussions for the years 2020 through 2024.
Why It Matters
This filing provides transparency into how Agios Pharmaceuticals compensates its top executives, which can influence investor decisions and employee morale.
Risk Assessment
Risk Level: low — This is a routine annual filing (DEF 14A) that primarily discloses executive compensation and corporate governance information, with no immediate indication of significant financial distress or operational risk.
Key Numbers
- 2024-12-31 — Fiscal Year End (Reporting period for compensation details)
- 20250425 — Filing Date (Date the DEF 14A was submitted to the SEC)
Key Players & Entities
- AGIOS PHARMACEUTICALS, INC. (company) — Filer
- Brian Goff (person) — Member involved in compensation
- Jacqualyn A. Fouse (person) — Member involved in compensation
- 0001193125-25-096719 (dollar_amount) — Accession Number
FAQ
What is the primary purpose of a DEF 14A filing?
A DEF 14A filing, also known as a Proxy Statement, is used to solicit shareholder votes on important corporate matters, including the election of directors and executive compensation.
Who are the key individuals mentioned in relation to compensation for Agios Pharmaceuticals?
Brian Goff and Jacqualyn A. Fouse are mentioned as members involved in compensation discussions for the fiscal years 2020 through 2024.
What is the fiscal year end for Agios Pharmaceuticals as indicated in this filing?
The fiscal year end for Agios Pharmaceuticals is December 31st, as indicated by the reporting periods such as 2024-12-31.
When was this DEF 14A filing submitted to the SEC?
This DEF 14A filing was submitted to the SEC on April 25, 2025.
What is the Central Index Key (CIK) for Agios Pharmaceuticals?
The Central Index Key (CIK) for Agios Pharmaceuticals, Inc. is 0001439222.
Filing Details
This Form DEF 14A (Form DEF 14A) was filed with the SEC on April 25, 2025 by Brian Goff regarding AGIOS PHARMACEUTICALS, INC. (AGIO).